The University of Queensland

Preclinical studies of group A Streptococcal vaccine candidates (2010–2012)

Abstract:

Group A streptococcus causes 520,000 deaths each year. A safe and effective vaccine is not commercially available. We have identified 2 new protective candidate antigens, and we seek to undertake critical preclinical studies to provide further proof-of-concept data. This work will underpin commercial decisions by our industry partner (Wyeth) leading to human trials and the development of a safe group A streptococcal vaccine for human use.

Grant type:

NHMRC Development Grant

Researchers:

• 

  Professor Mark Walker

  Professorial Research Fellow & GL
  

  Institute for Molecular Bioscience

Funded by:

National Health and Medical Research Council